Insulinization in T2DM with Basal Analogues During COVID-19 Pandemic: Expert Opinion from an Indian Panel
Tóm tắt
The ongoing global pandemic of the coronavirus disease 2019 (COVID-19) has placed a severe strain on the management of chronic conditions like diabetes. Optimal glycemic control is always important, but more so in the existing environment of COVID-19. In this context, timely insulinization to achieve optimal glycemic control assumes major significance. However, given the challenges associated with the pandemic like restrictions of movement and access to healthcare resources, a simple and easy way to initiate and optimize insulin therapy in people with uncontrolled diabetes is required. With this premise, a group of clinical experts comprising diabetologists and endocrinologists from India discussed the challenges and potential solutions for insulin initiation, titration, and optimization in type 2 diabetes mellitus (T2DM) during the COVID-19 pandemic and how basal insulin can be a good option in this situation owing to its unique set of advantages like lower risk of hypoglycemia, ease of training, need for less monitoring, better adherence, flexibility of using oral antidiabetic drugs, and improved quality of life compared to other insulin regimens. The panel agreed that the existing challenges should not be a reason to delay insulin initiation in people with uncontrolled T2DM and provided recommendations, which included potential solutions for initiating insulin in the absence or restriction of in-person consultations; the dose of insulin at initiation; the type of insulin preferred for simplified regimen and best practices for optimal titration to achieve glycemic targets during the pandemic. Practical and easily implementable tips for patients and involvement of stakeholders (caregivers and healthcare providers) to facilitate insulin acceptance were also outlined by the expert panel. Simplified and convenient insulin regimens like basal insulin analogues are advised during and following the pandemic in order to achieve glycemic control in people with uncontrolled T2DM.
Tài liệu tham khảo
Coronavirus disease 2019 (COVID-19) Situation Report-94. World Health Organization. 2020. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200423-sitrep-94-covid-19.pdf?sfvrsn=b8304bf0_4. Accessed 5 Oct 2020.
Bornstein SR, Rubino F, Khunti K, et al. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol. 2020;8:546–50.
Hussain A, Bhowmik B, do Vale Moreira NC. COVID-19 and diabetes: knowledge in progress. Diabetes Res Clin Pract. 2020;162:108142.
Ghosal S, Sinha B, Majumder M, et al. Estimation of effects of nationwide lockdown for containing coronavirus infection on worsening of glycosylated haemoglobin and increase in diabetes-related complications: a simulation model using multivariate regression analysis. Diabetes Metab Syndr. 2020;14:319–23.
Kalra S, Bajaj S, Sharma SK, et al. A practitioner’s toolkit for insulin motivation in adults with type 1 and type 2 diabetes mellitus: evidence-based recommendations from an international expert panel. Diabetes Ther. 2020;11:585–606.
Managing diabetes during the COVID-19 pandemic. https://www.cebm.net/covid-19/managing-diabetes-during-the-covid-19-pandemic/. Accessed 6 July 2020.
The RAND/UCLA appropriateness method user’s manual. https://www.rand.org/content/dam/rand/pubs/monograph_reports/2011/MR1269.pdf. Accessed 6 July 2020.
Hirsch IB, Gaudiani LM. Using insulin to treat poorly controlled type 2 diabetes in 2020. JAMA. 2020. https://doi.org/10.1001/jama.2020.1303.
Ghosh S, Ghosh R. Glargine-300: an updated literature review on randomized controlled trials and real-world studies. World J Diabetes. 2020;11:100–14.
American Diabetes Association. Standards of medical care in diabetes—2020. https://care.diabetesjournals.org/content/43/Supplement_1/S98.full-text.pdf. Accessed 6 July 2020.
Jain SM, Seshadri K, Unnikrishnan AG, et al. Best practices and tools for titrating basal insulins: expert opinion from an Indian panel via the modified Delphi consensus method. Diabetes Ther. 2020;11:621–32.
Rosenstock J, Cheng A, Ritzel R, et al. More similarities than differences testing insulin glargine 300 units/mL versus insulin degludec 100 units/mL in insulin-naive type 2 diabetes: the randomized head-to-head BRIGHT trial. Diabetes Care. 2018;41(10):2147–54. https://doi.org/10.2337/dc18-0559.
Kalra S, Gupta Y, Unnikrishnan AG. Flexibility in insulin prescription. Indian J Endocrinol Metab. 2016;20:408–11.
Hanefeld M, Koehler C, Hoffmann C, et al. Effect of targeting normal fasting glucose levels with basal insulin glargine on glycaemic variability and risk of hypoglycaemia: a randomized, controlled study in patients with early type 2 diabetes. Diabet Med. 2010;27:175–80.
Janka HU, Plewe G, Riddle MC, et al. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care. 2005;28:254–9. https://doi.org/10.2337/diacare.28.2.254.
Kumar S, Jang HC, Demirağ NG, et al. Efficacy and safety of once-daily insulin degludec/insulin aspart compared with once-daily insulin glargine in participants with type 2 diabetes: a randomized, treat-to-target study. Diabet Med. 2017;34:180–8. https://doi.org/10.1111/dme.13125.
Kumar A, Franek E, Wise J, et al. Efficacy and safety of once-daily insulin degludec/insulin aspart versus insulin glargine (U100) for 52 weeks in insulin-naïve patients with type 2 diabetes: a randomized controlled trial. PLoS One. 2016;11:e0163350.
Baser O, Tangirala K, Wei W, et al. Real-world outcomes of initiating insulin glargine-based treatment versus premixed analog insulins among US patients with type 2 diabetes failing oral antidiabetic drugs. Clinicoecon Outcomes Res. 2013;5:497–505.
Saini SD, Schoenfeld P, Kaulback K, et al. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care. 2009;15:e22-33.
Singh AK, Khunti K. Assessment of risk, severity, mortality, glycemic control and antidiabetic agents in patients with diabetes and COVID-19: a narrative review. Diabetes Res Clin Pract. 2020;165:108266.